DNAG Endlich!!!!!!!!!!!!! - 500 Beiträge pro Seite

[FCHennes]

DNAPrint genomics Receives Notice of Allowance for Patent for Processing Gene Sequence Data
Thursday October 27, 7:00 am ET

SARASOTA, Fla., Oct. 27, 2005 (PRIMEZONE) -- DNAPrint genomics, Inc. (OTC BBNAG.OB - News), a developer of genomics-based products and services, today announced that it has been granted a notice of allowance from the U.S. Patent and Trademark Office for its patent application for Efficient Methods and Apparatus for High-Throughput Processing of Gene Sequence Data.

ADVERTISEMENT
``Though we are all 99.9% identical at the level of our DNA, it is the 0.1% difference called polymorphism that accounts for our individuality,`` stated Tony N. Frudakis, Ph.D., DNAPrint`s founder and Chief Scientific Officer. ``The technology our patent application covers relates to methods useful for measuring polymorphisms in and around genes that are part of large gene families, a task that traditionally has been problematic for the molecular genetics community.``

Geneticists use ``molecular addresses`` to query and study specific genes much like a postman uses a street address to find the recipient of a letter. The methods covered in the patent are useful when there are several genes with the same or substantially similar ``sequence`` addresses. Many of the genes that are involved in drug metabolism and response are members of large gene families.

This is the first patent for which the Company applied. The methods covered in the application, first drafted in 2001, were originally developed to power DNAPrint`s unique approach to pharmacogenomics research, which is aimed at understanding why people respond uniquely to drugs.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. (http://www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company`s first theranostic product (drug/test combination) is PT-401, a ``Super EPO`` (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint`s family of products for the law enforcement forensics and consumer markets include DNAWITNESS, RETINOME, ANCESTRYbyDNA and EURO-DNA.

Forward Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


Contact:

DNAPrint genomics, Inc.
Richard Gabriel, President and CEO
[phone]

The Wall Street Group, Inc.
Ron Stabiner
[phone]

Source: DNAPrint genomics, Inc.

Ich denke mit dem Satz, sollte es nun losgehen!!

This is the first patent for which the Company applied. The methods covered in the application, first drafted in 2001, were originally developed to power DNAPrint`s unique approach to pharmacogenomics research, which is aimed at understanding why people respond uniquely to drugs.

[brokersvenja007]

endlich.....

jetzt heißt es kaufen!!!!!!!!!!!!!!

wenn man stücke bekommt...
grüße
svenja

[brokersvenja007]

langsam kommt doch schon bewegung rein,...aktuell RT 0,019

mal ordentliche 30% plus im depot :-)

danke hennes
gute arbeit
svenja

[FCHennes]

Na also!
Seit ein paar Tagen wieder Bewegung drin. Wieder mehr Umsatz und heute im Plus. Mal sehen wo wir heute abend landen. Die 0,016 USD müssten wir nehmen können!

[Michiko]

Manno! Schon wieder dieses Sch****-Gepushe.

Ne Winzig-News und gleich werden wieder Threads eröffnet, die die Anleger reintreiben sollen!
Als ob die alten nicht dumm genug gewesen wären!!

Wollt Ihr die Leute verarschen oder seid Ihr einfach nur zu dumm!?!

[Optimierer]

Hi,

Frukadis, der größte Bandit dieser Schrottfirma.

Opti...

[FCHennes]

DNAPrint Genomics Acquires Kenna Technologies
Tuesday November 1, 7:00 am ET


Key Processes Will Enable Development of Personalized Medicine or `Theranostics` Using Test/Drug Combinations


SARASOTA, FL--(MARKET WIRE)--Nov 1, 2005 -- DNAPrint(TM) genomics, Inc. (OTC BBNAG.OB - News), a developer of genomics-based products and services, today announced that it has acquired Kenna Technologies, Inc., of West Chester, Pa., a private company which builds computer models that mimic complex biological systems.
ADVERTISEMENT


Under terms of the agreement, Kenna`s shareholders exchanged all of the company`s outstanding shares for 1.5 million shares of DNAPrint genomics Common Stock. The transaction was effective on Tuesday, Oct. 25, 2005.

"The acquisition of Kenna and its computational biology process, provides substantial synergies with our pharmacogenomics applications," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint genomics. "We believe Kenna`s technologies will lead to shorter and less expensive drug development times, and represent a powerful tool in our company`s search to develop programs for personalized medicine, and test/drug combinations targeting a specific group of patients."

Computational biology models (also called In silico technology,) incorporate the vast datasets and fragmented knowledge of experimentalists and can be a crucial requirement when developing effective therapies and diagnostic products.

"Initially, the Kenna team will support the clinical development of DNAPrint`s PT-401 Super EPO erythropoietin dimer for the treatment of anemia and renal failure," stated Kenna co-founder Barbara Handelin, Ph.D, who joins DNAPrint as Director of Diagnostics and General Manager of Computational Biology. "We will provide simulations to help design optimal clinical trials with respect to dosing, patient selection factors and trial duration."

As a result of the acquisition, DNAPrint also gains access to Kenna`s BoneFusion(TM) and CellCycleFusion(TM) models. BoneFusion simulates the processes in bone remodeling that underlie diseases like osteoporosis, while CellCycleFusion simulates the molecular pathways that control basic cellular functions. These pathways are common targets of current cancer therapies.

"Simply put, DNAPrint will utilize computational modeling to develop drugs more efficiently," said DNAPrint President and Chief Executive Officer Richard Gabriel. "It will play a valuable role in our Company`s efforts to pursue the development of drugs which maximize efficacy and minimize side effects by tailoring medications for specific individuals and well-defined population sectors."

About DNAPrint

DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company`s first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint`s family of products for the law enforcement forensics and consumer markets include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.



Contact:
Company Contact:
Richard Gabriel
President and CEO
941-366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848



--------------------------------------------------------------------------------
Source: DNAprint Genomics, Inc.



Und weiter geht es mit guten Nachrichten. Die Post geht hier bald so was von ab, da werden einige von euch noch hinterher schauen. Guckt mal nach, was sich alleine in den letzten 3 Wochen an News getan hat.....
Ich bin zwar auch noch dick im Minus, habe aber noch mal nachgelegt und bin voll optimistisch, dass da die Wende kommt. Und zwar ganz DICK!

[gracia]

es existieren bei yahoo msn und unter eoddata keine vollständigen datensätze. eine charttechnische analyse ist nicht möglich. was veranlasst sie dieses opjekt zu analysieren und wo erhalten sie vollständige datensätze für dieses objekt?

[FCHennes]

@gracia

alles in Ordnung?????????

[gracia]

danke, alles in ordnung, unter folgendem link
http://finance.yahoo.com/q/cq?d=v1&s=2218769.BE+2218769.F+DN…
finde ich alle papiere von dnaprint.
die kurshistorien sind dürftig. eine analyse mit den daten ist unmöglich.
nutzten sie andere datenquellen, andere börsenplätze, ?
was macht die firma in ihren augen interessant ?
kennen sie die firma ?

[Michiko]

[posting]18.534.796 von gracia am 01.11.05 19:19:28[/posting]gracia,

Sie sind seit heute hier angemeldet, also völlig neu hier onboard.

Falls Sie Hintergrund-Informationen über DNAPrint wünschen, schauen Sie bitte hier nach:

Thread: DNAG: Hass oder Liebe - dazwischen geht nichts!

[Michiko]

Sorry, ich meine

Thread: DNAG: Hass oder Liebe - dazwischen geht nichts!

[FCHennes]

@gracia

Ich kenne von der Firma nur die veröffentlichten Nachrichten, die hier immer im Board von mir oder anderen veröffentlicht werden. Und die finde ich richtig super!
Wenn Sie, ich betone Sie, jedoch mehr rausfinden mit ihrer eigenen Suchmaschine, freue ich mich auf weitere Infos.
Aber: Für sie kommt dann wohl doch eher ne BASF oder ne Bayer Aktie in Frage. Da können Sie sicherlich auch noch einiges rausfinden in Ihrer freien Zeit.
Viel Spaß dabei!

[FCHennes]

Na also, geht doch!!!!

[FCHennes]

Liebe Leute,

es geht los!!!

Anschnallen!

Gleich über 0,02 US-cent!!

[i2fan]

sieht heute wieder gut aus. Wenns so weiter geht, sind wir nächste Woche über 0,03 US cents.

[FCHennes]

[BRBa]

Das sieht ja Super aus hier

http://stockcharts.com/gallery/?dnag

[FCHennes]

@BRBa

Vielen Dank. Das ist ja ne geile Seite.
Kannte ich noch gar nicht.
Hier kann sich jeder noch mal überlegen, doch noch welche zu kaufen, wenn er noch keine hat.
DNAG hat mit den positiven Meldungen den Rebound eingeleitet!!!

[Der-Gesalbte]

@Hennes,

ist dies die Trendwende? Wie weit kann das Papier steigen?

Gruß

Gesalbter

[FCHennes]

@Gesalbte

Sicherlich ist hier viel Risiko dabei, aber an Potenzial noch einiges drauf hat, da das Ding unheimlich viel aufholen kann und grad damit beginnt.

Ich bin der Meinung, dass man hier richtig Geld verdienen kann. Am meisten stimmen mich die letzten Meldungen positiv wg. TV Sendung und auch Zusammenarbeit mit neuen Partnern. Und deswegen habe ich viel investiert.

[FCHennes]

Das hier wird das Ding heute nach oben schießen!!!

Die News werden von Tag zu Tag ja immer geiler!!!!

Und die Häufigkeit der guten Nachrichten nimmt immer mehr zu!!!

Wer es noch bemerkt hat:

Die sind auf dem ganz ganz richtigen Weg!!!!

Press Release Source: DNAPrint genomics, Inc.

DNAPrint Genomics Executives to Attend World Drug Discovery & Development Conference in Copenhagen
Friday November 4, 7:00 am ET

SARASOTA, FL--(MARKET WIRE)--Nov 4, 2005 -- DNAPrint(TM) genomics, Inc. (OTC BBNAG.OB - News), a developer of genomics-based products and services, today announced that it will be participating in the World Drug Discovery & Development Summit on Tuesday and Wednesday, Nov. 29-30, 2005 in Copenhagen, Denmark.

ADVERTISEMENT
"The Summit comes at a time when DNAPrint genomics is actively pursuing the development of pharmacogenomic products that include test/drug combinations based on inherited gene characteristics. These test/drug combinations are designed to optimize patient response and improve efficacy," stated Hector J. Gomez, M.D., Ph.D., the Company`s Chairman and Chief Medical Officer. "The Summit is an excellent opportunity to participate in targeted meetings with pharmaceutical industry representatives and to discuss our Company`s advances in the field of personalized medicine."

Other top DNAPrint executives attending the summit, which is sponsored by the London-based World Trade Group, are President and Chief Executive Office Richard Gabriel and Company Founder and Chief Scientific Officer Tony N. Frudakis.

"This conference presents us a forum to showcase not only our drug development, but also how our technologies, products and services can help the pharmaceutical companies accelerate their own research and development programs," Mr. Gabriel said.

"The development of pharmaceuticals that improve the quality of life for medical patients has been an over-riding goal of our Company from its beginning," Dr. Frudakis stated. "Our research in drug development is well under-way and our newly formed DNAPrint Pharmaceutical subsidiary emphasizes the importance we place on this objective."

About DNAPrint

DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company`s first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint`s family of products for the law enforcement forensics and consumer markets include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


Contact:

Company Contact:
Richard Gabriel
President and CEO
941-366-3400
or
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848

[BRBa]

[posting]18.631.735 von FCHennes am 07.11.05 11:32:55[/posting]0,0222/0,0223$

[FCHennes]

Da sin ma dabei, das ist priiiiiiima!

VIVA DNAG!!

[fohlenpelzig]

@Hennes:

Da simma dabei das is priima: Köln 2.Liga!
Wir scheißen auf die Kohle und den UEFA-Cup,
wir saufen lieber 100 Kölsch und steigen wieder ab!

fohlenpelzig

[FCHennes]

Ist das ein Rebound???

Wahnsin!!!

Die ist jetzt nicht megr zu halten

[FCHennes]

Umsätze sind ja wieder etwas weniger geworden.
Mal sehen, wann wir wieder starten.
Aber wenn wir und jetzt um die 0,016 US-cent halten ist es ja in Ordnung.

[WissenMacht]

DNAPrint Genomics and SeraCare`s Genomics Collaborative Combine to Improve Outcome for Ovarian Cancer Treatment
11/14/2005 7:00:06 AM





SARASOTA, FL AND OCEANSIDE, CA, Nov 14, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics, Inc. (DNAG) and the Cambridge, Mass.-based Genomics Collaborative Division of SeraCare Life Sciences, Inc., today announced that they have begun collaboration on a project designed to improve treatment for patients with ovarian cancer.

MARKETWATCH TOP NEWS
U.S. stocks drift lower in final hour of trading
Wal-Mart profit rises; forecasts `good` holiday
Knight Ridder shares up; board to mull publisher`s sale
Georgia-Pacific rallies near $48-a-share buyout offer
Host Marriott paying $4.1B for 38 Starwood properties
Sign up for FREE e-Newsletters

TRACK THESE TOPICS
My Portfolio Alerts
Company: Dnaprint Genomics Inc Add
Create
Get Breaking News sent directly to your inbox
Create A Portfolio | Create An Alert
"The goal is to identify genetic factors that will enable physicians to predict the outcome and efficacy of carboplatin/tamoxifen treatment, a standard therapy for victims of breast cancer," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint genomics. "Combining Genomics Collaborative`s extensive network of physician-managed centers with DNAPrint`s proprietary genetic testing, the genetic characteristics of 200 women will be studied by comparing those who responded to a standard carboplatin/tamoxifen regimen for breast cancer with those who did not."

"We anticipate that the study`s findings may enable physicians to identify likely non-responders before initiation of carboplatin/tamoxifen therapy so that an alternative treatment can be utilized from the outset," stated Kevin Krenitsky, M.D., Senior Vice President and Division Head of Genomics Collaborative. "We hope to improve the outcome of treatment for patients afflicted with this challenging condition."

This marks the second collaborative project between DNAPrint and Genetics Collaborative.

About SeraCare Life Sciences

SeraCare Life Sciences, Inc. is a manufacturer and supplier of biological materials and services essential for the use and manufacture of diagnostic tests and the discovery, development and commercial production of pharmaceuticals. The Company`s offerings include plasma-based therapeutic products, diagnostic products and reagents, cell culture products, specialty plasmas, in vitro stabilizers, and the Global Repository(R), comprised of clinical samples (DNA, RNA, tissue, and serum) for use in the drug discovery and development processes. SeraCare is headquartered in Oceanside, CA, and maintains facilities in Cambridge and West Bridgewater, MA; Frederick and Gaithersburg, MD; and Hatboro, PA. For more information please visit http://www.seracare.com.

About DNAPrint

DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company`s proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company`s first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the company`s drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).

Forward Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

[FCHennes]

Form 10QSB for DNAPRINT GENOMICS INC

15-Nov-2005

Quarterly Report


Item 2. MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The "forward-looking statements" safe harbor does not apply to our company because we issue "penny stock" and are excluded from the safe harbor pursuant to
Section 27A(b)(1)(C) of the Securities Act of 1933, as amended, and Section 21E(b)(1)(C) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Nevertheless, this Quarterly Report on Form 10-QSB contains forward-looking statements. In addition, from time to time, the Company or its representatives have made or may make other forward-looking statements orally or in writing. Such statements may include, without being limited to, statements concerning anticipated financial performance, future revenues or earnings, business prospects, projected ventures, new products, anticipated market performance and similar matters. The words "plan," "budget, "intend," "anticipate," "project," "estimate," "expect," "may," "might," "believe," "potential," "could," "should," "would" and similar statements are intended to be among the statements that are forward-looking statements. We caution our readers that, because such statements reflect the reality of risk and uncertainty that is inherent in doing business, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to, those set forth in the Company`s Form 10-KSB for 2004 in the Management`s Discussion and Analysis of Financial Condition and Results of Operations under the heading "Certain Factors Which May Affect the Company`s Future Performance" which are incorporated herein by reference. Readers are cautioned not to place undue reliance on these forward-looking statements, which are made as of the date of this report. Except as otherwise required to be disclosed in periodic reports required to be filed by companies registered under the Exchange Act by the rules of the SEC, the Company has no duty and undertakes no obligation to update such statements.

The following discussion and analysis should be read in conjunction with the balance sheets as of December 31, 2004 and September 30, 2005 and the financial statements for the three and nine months ended September 30, 2005 and 2004 included with this Form 10-QSB.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that have a significant impact on the results we report in our financial statements. Some of our accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Actual results may differ from these estimates under different assumptions or conditions. Below, we discuss this further, as well as the estimates and judgments involved.

Asset Impairment

We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset exceeds its fair value and may not be recoverable. In performing the review for recoverability, we estimate the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows (undiscounted and without interest charges) is less than the carrying amount of the asset, an impairment loss is recognized. Otherwise, an impairment loss is not recognized. Management estimates the fair value and the estimated future cash flows expected. Any changes in these estimates could impact whether there was impairment and the amount of the impairment. Since we are in the development stage, we do not have much history to determine our estimated cash flows. If we do not meet our targeted cash flows for our services and if the estimated disposition of the equipment is lower, this could result in a write-down of our equipment. Our equipment is very specialized equipment related to genomics research, and there probably will not be a large demand for our used equipment. The amount of our net fixed assets is the amount of the maximum risk if our assumptions were not correct. Each year the assets will have higher depreciation and the maximum risk will decrease correspondingly.

Allocation of Research and Development Costs

Prior to 2004, our research and development costs were derived by allocating certain costs based on total labor effort. The percentage of total labor effort expended on research and development was an estimate by management. During 2004, we refined our process of allocating costs by identifying and directly expensing certain costs related to research and development and allocating certain other costs based on total labor effort that is estimated by management and employees. With some of these costs, a percentage of a total purchase order price is allocated to research and development. Also during 2004, we implemented a time card process that gives us a more refined estimate of certain employees` time. During 2005, as raw materials became significant, we began recording inventory for our raw materials. As the raw materials are used, they are charged to research and development expense based upon actual usage for research and development. We continue to refine our process of identifying time associated with research and development. These refinements to estimates could increase or decrease our income statement expense categories of research and development, cost of sales and selling, general and administrative. Over time we believe this change in allocating costs will result in a lower allocation of administrative costs to research and development. Also, as we hire employees, the department in which the employee is hired will have a direct impact on the allocation of administrative costs to research and development. For example if a person is hired in research and development, the allocation to research and development for other administrative costs will increase because labor effort percentage for research and development will have increased. If a person is hired in administration, the allocation to research and development for other administrative costs will decrease because the labor effort percentage for research and development will have decreased. Changes to these estimates could have a significant impact on the accrual and related compensation expense and/or deferred compensation.

Valuation of Goodwill

Goodwill is reviewed annually for impairment or more frequently if impairment indicators arise. This annual impairment test is performed in the last quarter of each fiscal year. The goodwill impairment test requires a comparison of the fair value of the Company to the amount of goodwill recorded. If this comparison reflects impairment, then the loss would be measured as the excess of recorded goodwill over its implied fair value. Although the Company`s management believes that the estimates and assumptions used are reasonable, actual results could differ.

Estimation of Fair Market Value

We use the Black Scholes Option Model to determine fair market value in certain instances (i.e. to value warrants and the intrinsic value of the convertible debt and non-detachable warrants). The Black Scholes Option Model requires estimated assumptions in its computation. We estimate the assumptions used in each calculation based upon the transaction term and what we believe most appropriately reflects the transaction. If different estimates of the assumptions were used, it could result in different fair market value amounts being calculated. Additionally, various methods can be used to determine the fair market value of the warrant. If a different model were used besides the Black Scholes Option Model, it could result in different fair market value amounts being calculated.

Summary

Although we have been in existence for a number of years, management`s efforts to develop our business have not yet resulted in the generation of significant revenues. We have chosen to focus on increasing sales volume in the consumer and forensic markets while continuing to develop products for introduction to the pharmacogenomics market. During 2005, we added seven new distributors to sell our consumer products.

We continue to devote substantially all of our efforts in initiating and developing our planned principal operations. We have reported that while sales of our ancestry product, ANCESTRYbyDNA(TM) and paternity services have increased compared to the prior year, sales of forensic product DNAWitness(TM) and genotyping services decreased. Our new consumer product EURO-DNA(TM) 1.0 was introduced in the marketplace in late 2004. We acquired Trace Genetics late during the second quarter which will contribute revenues during the last half of 2005. Trace Genetics brings two new complementary technologies to our autosomal testing for determining the percentage of a person`s ancestry: Y-chromosome testing for tracing ancestry by following the direct paternal line and mitochondrial (mtDNA (TM)) testing for the direct maternal line. Trace also maintains one of the largest Native American mtDNA(TM) databanks which, when combined with DNAPrint`s, will be one of the largest in North America. Other similarly large databases are controlled by groups such as the Sorensen foundation, various Native American foundations and tribes, and some Universities. Our pharmacogenomics products are still in development. Because our products are relatively new to the market, we believe that sales will continue to fluctuate from period to period until we can better determine through continued market research and experience how and where to best market and sell the products.

Management continues to implement and refine operational procedures and controls to support future growth and development. We intend to support research and development as a vital component of our overall growth strategy. Until potential customers are familiar with our technology and products, which will come from continued research and development and proven market use, it is unlikely that we will generate significant revenue.

Management plans to continue to focus on increasing sales in the market areas of forensics and genealogy and to move towards the introduction of new and expanded products in these markets. During July 2005, we expanded our DNAWitness(TM) product suite which now includes:

DNAWitness(TM) 2.5 -- Tests crime scene DNA to assist detectives, forensic scientists and medical examiners in corroborating eyewitness reports and confirming suspect identities. DNAWitness(TM) 2.5 provides a BioGeographical Ancestry report that includes a photo database for reference samples of individuals. Reported ancestral origins are Sub-Saharan African, Native American, East Asian and Indo-European.

EuroWitness(TM) 1.0 -- Tests crime scene DNA to determine more specific geographic origins if the test sample ancestry is 50% or more Indo-European. EUROWitness 1.0 provides a BioGeographical Ancestry report that includes relative percentages of Northwest European, Southeast European, Middle Eastern or South Asian.

Retinome(TM) -- A predictive test for individual eye color from DNA. Retinome(TM) predicts eye color if the sample is 50% or greater European ancestry as to whether eye color is blue, mostly blue, brown or mostly brown. A representative eye photo database is also provided along with relevant photo database pictures of the individual references.

STR-Witness(TM) -- A genetic "matching" used as a bar code to track and report the samples. STR-Witness(TM) is the same test used for determining an individual`s identity from an available DNA sample. Crime labs run this test to screen the Federal Bureau of Investigation`s Combined DNA Index System (CODIS) database for possible matches.

DNAWitness-Y(TM) -- A new Y-chromosome test that determines the direct paternal ancestral lineage from the male sex chromosome. DNAWitness-Y(TM) can be used as an identification tool in cases where a mixture of male and female samples exists.

DNAWitness-Mito(TM) -- A new mitochondrial DNA test that examines ancestral lineages along the maternal line. DNAWitness-Mito(TM) can be used as an identification tool when other DNA testing fails to yield results or the DNA sample is too deteriorated.

We plan to continue market research within both the forensics and genealogy segments to further expand our knowledge and understanding of the most efficient way to market and sell our products.

In our pharmacogenomics segment, we will continue work on OVANOME(TM), a Taxol screening diagnostic test, and STATINOME(TM), a test for the cardiac drug market, which are both currently under development. We will also continue our efforts on other research and development projects that are underway. Our OVANOME(TM) technology is under development with researchers at the Moffitt Cancer Center in Tampa, Florida, and we are in the midst of completing an initial 80 person trial under an approved IRB (Internal Review Board) which approves all clinical trial related work at the center. We are also enrolling an additional 200 subjects to further validate and support the data we obtained in our earlier trial. We will continue to explore joint venture opportunities, particularly within the pharmacogenomic segment, in order to potentially expand our position within the pharmaceutical market. A major goal of our joint venture program is to seek opportunities for a drug pipeline acquisition. Our recent licensing of a `Super` Erythropoietin (EPO) molecule from Beth Israel Deaconess Hospital (BIDMC) is a step forward in that direction. We plan to combine our ability to screen patients and track patient response to the standard form of EPO when compared to our newer, `Super EPO`. We believe this will improve our clinical efficacy and reduce the unwanted side-effects of standard EPO treatment for anemia. We plan to begin development of our new product and have GMP material ready for early stage pre-clinical development work by or during the first quarter of 2006 in accordance with our licensing agreement with BIDMC.

Additionally, on June 7, 2005, we entered into a consulting agreement with Dr. Arthur Sytkowski, the Director of BIMDC to consult on the development of a new, more potent and longer acting form of EPO. Under the consulting agreement, Dr. Sytkowski has agreed to perform certain consulting services, including advising on medical, regulatory and patent issues, training personnel and providing assistance with EPO research and development. Also during late June, we entered into a collaborative research agreement with BIDMC to provide three researchers to us over a six-month period to conduct certain research work related to our EPO research.

We anticipate beginning to work with clinicians at Massachusetts General Hospital for patient monitoring of standard EPO treatment of Kidney dialysis patients. Assuming we file an Investigational New Drug Application (IND) and it is approved, we hope to commence clinical studies at Massachusetts General and other centers that will be identified over time. We do not anticipate filing an IND application with the FDA during 2006. At present we are developing a manufacturing process for the PT-401 and also preparing for cGMP manufacturing of the product for pre-clinical development work. We have retained an experienced developer and manufacturer of EPO like products, and we will be advancing this development effort through the balance of this year and into 2006.

On October 25, 2005, we entered into an exclusive Licensing Agreement (the "License") with Dr. Mark Froimowitz to develop a series of methylphenidate analogs or Ritalin-like compounds targeting the clinical development of enhanced pharmaceuticals for the treatment of drug addiction, attention deficit hyperactivity disorder ("ADHD"), and depression. The licensed compounds are analogs of Ritalin, a well-known drug used for treatment of ADHD. The analogs are designed specifically to have a slow onset and increased half-life in the bloodstream, thus reducing a patient`s required daily dosage and the potential for drug abuse. We have the exclusive right to develop, use, market and sell products derived from the licensed compounds.

On October 25, 2005, we acquired all of the stock of Kenna Technologies, Inc. ("Kenna"). Kenna develops software and related technologies for building computational models that mimic complex biological systems. We expect that Kenna`s computational models will become key components for our development of more effective therapies and diagnostic products. In acquiring Kenna, we also gain access to Kenna`s BoneFusion and CellCycleFusion models, which simulate bone remodeling processes and molecular pathways. These pathways are common targets of current cancer therapies. We exchanged 1,500,000 shares of our common stock for all the outstanding shares of Kenna. In addition, we hired certain key employees of Kenna, including Drs. Barbara Handelin and Tandy Herrin, who will support the clinical development of our PT-401 with simulations to help design optimal clinical trials.

Internally, management will continue to develop and implement organizational policies and procedures to increase operating efficiency and move us closer to our goal of attaining and maintaining our planned principal operations.

Our plan of operations for the ensuing twelve months includes efforts to: 1) increase sales of our existing products and services; 2) introduce new and expanded products and services in the genealogy and forensic markets; 3) continue promoting our genotyping and paternity services while continuing to concentrate on research and development for both our existing products and our anticipated pharmacogenomic products and services. We expect to add personnel in the laboratory and in administration, as growth warrants. Capital expenditures needed for the next twelve months are discussed below under the section entitled "Liquidity and Capital Resources".

The following discussion of our historical financial results should be read against this background.

Results of Operations

Three and nine months ended September 30, 2005 compared to the three and nine months ended September 30, 2004

Revenues and Cost of Sales

During the three and nine months ended September 30, 2005 and 2004, revenues were $316,983 and $906,470 for 2005, respectively and $165,647 and $648,925 for 2004, respectively. A $151,336 increase in revenues for the third quarter from the prior period is a 91% increase while a $257,545 increase in revenues for the nine month period ending September 30, 2005 compared to the prior period is a 40% increase. In addition to the revenues recognized in the accompanying statement of operations, we also have recorded deferred revenues of $113,792 as of September 30, 2005. Deferred revenue resulted from some ANCESTRYbyDNA(TM) and EURO-DNA(TM) client testing that was not complete as of September 30, 2005. These amounts will be recognized as revenue in the fourth quarter of 2005.

The approximately $151,000 increase in revenues for the three months ended September 30, 2005 compared to the same period in the prior year is mainly the result of our ANCESTRYbyDNA(TM) revenues increasing by approximately $126,000, our paternity services increasing by approximately $10,000 and EURO-DNA(TM) revenues increasing approximately $31,000 compared to the same period in the prior year. These increases are due to our increased promotion and marketing of these services. We recorded approximately $16,000 of revenues from our mtDNA(TM) product, $11,000 of revenues from our DNAWitness-Mito(TM) and $10,000 of revenues from our Y-chromosome products which were added to our product line when we acquired Trace Genetics. This was offset by a decrease of approximately $60,000 from our genotyping services and $8,000 from our DNAWitness(TM) sales. In addition, we had approximately $15,000 of other revenues.

The approximately $258,000 increase in revenues for the nine months ended September 30, 2005 compared to the same period in the prior year is a result of our ANCESTRYbyDNA(TM) revenues increasing by approximately $136,000, our paternity services increasing by approximately $89,000 and our EURO-DNA(TM) revenues increasing approximately $74,000 compared to the same period in the prior year. These increases are due to our increased promotion and marketing of these services. We recorded approximately $16,000 of revenues from our mtDNA(TM) product, $11,000 of revenues from our DNAWitness-Mito(TM) and $10,000 of revenues from our Y-chromosome products which were added to our product line when we acquired Trace Genetics. This was offset by a decrease of approximately $78,000 from our genotyping services and $15,000 from our DNAWitness(TM) sales. In addition, we had approximately $15,000 of other revenues.

Paternity sales are generated primarily through our various distributors and from our website www.ancestrybydna.com. The majority of the increase in sales during 2005 compared to 2004 was from a distributor that was added during the second quarter of 2004. Paternity testing is an add-on service, and we expect revenues to continue to fluctuate in this market. While we have not yet implemented a formal marketing and sales plan for this service, we continue to perform market research and gather information in order to define and implement a formal marketing strategy. One distributor accounted for approximately $105,000 of our paternity sales during the first nine months of 2005. We do not expect these revenues to continue for the balance of the year and are working hard to replace the potential short-fall. During the third quarter and into the last quarter we will be accelerating our direct marketing and mail campaign for our ANCESTRYbyDNA(TM) and DNAWitness(TM) products and services as well as the Trace Genetics products and services.

Genotyping sales were generated primarily through work with universities with one university being our major client of this service. The decrease of genotyping services of approximately $60,000 during the third quarter of 2005 compared to the same period in 2004 and approximately $78,000 during the nine months ended September 30, 2005 compared to the same period in 2004 was the result of decreased service provided to one university. To date, our genotyping service customers have come to us either through client referrals or our general website. In the future, we plan to concentrate our genotyping services on specific diseases, including cancer, neurological disorders, and heart disease. By concentrating on specific diseases, we hope to develop an expertise that will attract customers in those areas requiring external assistance and additional research capacity. One university accounted for approximately $150,000 of our genotyping sales during the first nine months of 2005.

As part of our on-going genotyping contract services work for one of our new customers, we have offered to perform ANCESTRYbyDNA testing services on 284 children suffering from a disease known as ALL or Acute Lymphocyte Leukemia and anticipate under a joint publication agreement to submit a manuscript for publication during 2006. Following this early pre-screening, the ALL program will test nearly 3,000 children afflicted with this disease in hopes that we will be better able to help the research hospital determine the genetic markers that are inherited and that may play a role in disease formation, advancement or remission. Treatment protocols or treatment regimes include multiple drug therapies and include, Taxol and Taxol like derivatives as well as other chemotherapy treatments and protocols. It is too early to determine the potential benefits to us, but we believe that our donation of our technology and services is crucial to the development of better and improved treatments for ALL. Currently, nearly 10-20% of the children afflicted with this disorder do not survive beyond 18-24 months after diagnosis. We believe that our technology combined with the research hospital`s other work and including the contracted genotyping work performed by us for them, may help in reducing this dreadful statistic.

We continue to market our DNAWitness(TM) product through marketing to various agencies, our attendance at trade shows and through our relationships with Lynn Peavey catalog, Orchid Biosciences, and ReliaGene Technologies. We continue to seek to develop other distributors of our services and products. During 2004, our products, DNAWitness(TM) 2.0, RETINOME, and EURO-Witness 1.0 were featured in the Lynn Peavey Company catalog and the Lynn Peavey Web site. We trained Lynn Peavey Company personnel to establish and conduct seminars and training programs for detectives, crime laboratory personnel and crime scene personnel on DNAWitness(TM). Similarly, we have trained nearly 2,000 forensic personnel that include detectives, prosecutors and forensic scientists about our technology and its use. We anticipate continuing to train personnel on the use of our technology and products throughout 2005. Because these are new products and there are no similar products being marketed, we believe that forensic revenues will continue to fluctuate as we continue to research the markets and refine our sales and marketing strategy for our products. We have identified and applied for several grants and submitted our technology for federal review for applications that include human identification and terrorist tracking. We have not experienced and do not anticipate any funding of our research and development or deployment of our technology into any of these applications in 2005. We believe that the restraint of our sales in the forensics market does not originate from a lack of desire to use the technology by the detective or the prosecutor but rather a lack of funding for the increased staff that will be required to review cold case files, open new investigations or identify missing persons from stored human remains. We believe that the bulk of our investigative support will come through local and regional police, fire and detective agencies that do not require any federal funding to use our services and technology. We will however, continue to pursue much larger applications for our technologies on a global basis and will participate in several forensic and biometric venues in the remainder of 2005 that offer us a broad platform exposure to the world market. We are also seeking distributors of our products and services on a global basis applying our technology wherever the need could arise.

During the third quarter of 2005 compared to the same period in 2004, our sales of ANCESTRYbyDNA(TM) increased approximately $126,000. This is due to increased awareness and interest in genealogy and increased advertising during the third quarter by us in several markets. During the nine months ended 2005 compared to the same period in 2004, our sales of ANCESTRYbyDNA(TM) increased by $136,000. When we introduced our ANCESTRYbyDNA(TM) 2.5 during 2004, we increased the pricing which has resulted in a lower volume of product sold, but at a higher margin. Also, the product is relatively new to the market, and we believe sales will continue to fluctuate from period to period until we can better determine through continued market research and time how and where to best market and sell . . .

[JoJo49]

Positive Ergebnisse führten Gesternabend kurz vor Börsenschluß zu Insiderkäufen. Bei der NASDAQ OTC Bulletin Board 0,0278 +7,34% 21:59 16.03. 5.953.380 Stück gingen über den Ladentisch, bin mal gespannt wie es Heute bei Börseneröffnung um 15:30 abgeht.
Allen Anlegern viel Erfolg ein schönes Wochenende und gute Gedanken

Performance
Zeitraum Veränderung Zeitraum Datum Kurs
1 Woche -20,00% 52W Hoch 14.07.2005 0,15
1 Monat +0,00% 52W Tief 27.10.2005 0,01
1 Jahr n.a. Jahreshoch 14.02.2006 0,038
laufendes Jahr +25,00% Jahrestief 26.01.2006 0,014
Geht es wieder auf 52 Wochen hoch von 0,15€ oder weiter?

[JoJo49]

Antwort auf Beitrag Nr.: 20.766.423 von JoJo49 am 17.03.06 14:05:23

Trotz Patentgenehmigungen und guter Nachrichten geht es mit dem Wert bergab.
M.M. nach sollten wir abwarten und Tee trinken.
Allen Anlegern weiterhin viel Erfolg und gute Gedanken


Interview With:
Richard Gabriel
President and CEO

Dated March 14, 2006



LOCATION
900 Cocoanut Ave.
Sarasota, FL
USA 34236

Phone [phone]
Fax [phone]
E-Mail: Info


OFFICERS
Richard Gabriel, BS, MBA
Director

Hector J. Gomez, MD, PhD
Chairman

Tony Frudakis, PhD
Director

Monica Tamborini
CFO & Chief Operations Officer

CORPORATE INFO
DNAPrintTM genomics, Inc. is a genomics science company focused on the sale of unique proprietary genetic testing products and services. The Company’s core patented and proprietary technologies for efficiently targeting single nucleotide polymorphisms (“SNPs”) enable us to provide novel predictive genetic tests at a significant cost advantage over our competitors.


LINKS
Homepage
Receive All Future Press Releases

FINANCIAL
Historical Prices
Reports
TRANSCRIPT OF INTERVIEW
WSR: Could you begin with an outline of the company’s origins, leading up to today’s activities?

DNAP: Very briefly, the company was started by our founder, Dr. Tony Frudakis. Somewhere around 1999 we were incorporated and then we were listed on the Bulletin Board Exchange. We focused primarily in the early stages on launching our products and services in, what we call biogeographical ancestry. The first products on the market were in the genealogy area, and this was to help the genealogists and people who are interested in their genetic ancestry to get a better identification. Most of the tests that were available at that time were very limited, Y chromosome and mitochondrial. These are only two chapters out of the 23-chapter book of the human chromosome. We scanned the entire chromosome and found a series of ancestry informative markers that were very influential and also very powerful in being able to determine where an individual came from; what part of the globe. We applied that first to the genealogy area. Later on, in about 2002, we did a presentation at a forensics conference. We were always looking to apply this to the pharmaceutical area, but we thought our entry into the forensics area would better serve us because it will help us validate. We would then have enough samples to be able to proceed into the pharmaceutical area, which wasn’t quite ready at that time for things like biogeographical ancestry and genetic ancestry. So, we have now done well over 100 criminal cases. Our most profound cases are the Louisiana serial killer case, which we just reviewed at the American Academy of Forensics Sciences in Seattle. We did a workshop along with a task force featuring our work on that case, and many other cases, of which we can’t discuss. We have two divisions: consumer products division and the ancestry division, and our quarterly year-end projections should be out very shortly. We’ve done quite well last year in advancing our sales revenue, not up to where we want them to be, but certainly we continue to increase our revenues there and we’ll continue to push in those two areas. We also acquired two other companies: Trace Genetics, in Richmond, California, and Ellipsis Biotherapeutics in Toronto. We have been focusing on licensing our technologies; there are three. One is the Glycated CD59 technology from Harvard, which we are advancing to determine diabetes. The Glycated CD59 appears to provide a better handle on diagnosing the ups and downs of diabetes in conjunction with the existing tests, which will help physicians and patients manage their diabetes better. The second area is in the, what we call, super EPO, that was also licensed from Beth Israel, which is also a Harvard affiliate, and that is a product that is a dimer of the standard EPO (we just did a press release on that today) and we have seen some very dramatic advancements in being able to clone up those products into cells. So, we are very excited about that. This product appears to work at a lower dose and is much more effective, but as in all drug development projects, we have a long way to go. We are selecting GMP manufacturing companies for the next leg of this development. And we’ve also, for this CD59, retained a CRO (clinical research organization) who are experts in diagnostics. The third area is in the neuro area, in particular, with Mass College of Pharmacy and Dr. Mark Froimowitz, and those compounds -- one lead compound is being evaluated by NIDA (the National Institute on Drug Abuse) for drug addiction and we have two other compounds that we’ve identified for attention deficit as well as depression, which is a new mechanism that Dr. Froimowitz has identified. So, we are advancing those and we are also coupling those with genotyping work in which we are able to identify the up and down regulation of particular genes that may either detrimentally impact the drug that we have in the pipeline or beneficially impact, and along with that, we will be doing our BioGeographical Ancestry analysis.

WSR: The company has clearly advanced on several fronts. What is the strategy moving ahead?

DNAP: The strategy is pretty straightforward because we are a public company and we are always looking for financial partners. We have two right now: Dutchess Equity Partners and La Jolla Ventures, which we’ve had for a quite a while. So, we’ve secured enough capital, but of course investment capital means investor dilution and the key to sustaining a low dilution is a high share price. And right now, we think the stock is undervalued especially in light of a recent report by Khandaker, where they evaluated our portfolio of products and technologies and did an across-the-board comparison and recommended, of course, that the stock was indeed low in price. So, we are looking to increase our share value and by securing and advancing many of these technologies to the next level, looking for partners and seeking additional financial partners and simultaneously increasing revenues, we hope to improve shareholder value over the next several years.

WSR: What is the potential growth for forensics in consumer products?

DNAP: We just came back from the ASCPT (American Society of Clinical Pharmacology and Therapeutics) in which we ran a workshop on the importance of biogeographical ancestry on patients’ identification and also administration of drugs, and many of the papers that were presented there were only using identified genotypes or genes. That’s all well and good, but the problem is even with leading gene products that the FDA has approved, for instance the herceptin gene, still in the patient population that it works in the women who have the HER2 gene, only about 60% of those patients actually respond to the medication that has been designed. So, there is still some radical difference between the responders and non-responders. Even though you’ve identified a genotype, it doesn’t yet quite help the physician identify those patients who aren’t going to respond. We believe that using biogeographical ancestry along with whole-genome genotyping, the BGA acts as a filter and helps to focus the research and to be able to develop technologies and diagnostics that will support new medicines.

WSR: What are some of the goals you’ve outlined for the close of 2006, with which we can use as a measure or benchmark in evaluating the progress of the company?

DNAP: Increased revenues is one. We’ve increased revenues since the management team came onboard; Dr. Gomez, myself, Ms. Tamborini, and Tony, and we’ve continued to advance revenues year by year. So, investors should expect and we hope to deliver an increased revenue stream over last year’s, which should be out within the next week or so. There was an increase from last year to this year as well. We also will be focusing on looking for marketing partners in particular, and launching new products. We have several new products that can be sold that are within, so to speak, our guidelines, that don’t have all of the restrictions on them that we will have once we go into formal FDA applications for either the diagnostics or the drugs. But these are products in the consumer as well as in the forensics area, and we continue to push in the forensics area. We believe that that is an area that if federal funding were appropriately channeled toward helping identify missing persons or remains so that missing persons can be matched to remains, as well as in serial killers, in helping to provide detectives with some idea as to what they should be looking for or corroborating with this identification of an individual, is just as important. And of course, the genetic ancestry; we now offer mitochondrial as well as the Y chromosome and our whole-genome research, and we will have new products coming out in that area in 2006 as well. It is a very exciting time, unfortunately diagnostics and drugs take a longer time; we should not expect to have any revenues from either of those in 2006.

WSR: What notable trends are influencing the way you position the company for future success?

DNAP: We have started working on the human populations early in the pharmaceutical arena in 2000. We started off with a technology called OVANOME which, believe it or not, is still in progress. The problem with OVANOME is that there are few ovarian cancer patients; i.e., women whose samples become available. So, we have a difficult time obtaining samples for that particular trial. But we continue to gather samples through the Moffitt and several other cancer centers that we’re working on and we plan on having discussions with the NCI as well as the FDA about this as soon as we have enough information available to do so. But that gives you an idea as to how difficult it is to develop new technology in the pharmaceutical area. People should continue to watch the FDA. Janet Woodcock just gave a speech at the ASCPT that pretty much told the industry that personalized medicine is an opportunity that the FDA believes is a reality. We also concur with her vision as well as that hopefully of the new director of the FDA. So, we see the FDA is actually leading the industry versus the industry leading. We know many of the pharmaceutical companies are using modified genetic ancestry, and we hope they are not going to be in violation of our patents once they are awarded, but if they are, then we will have a conversation with them.

WSR: What can you tell us about leveraging intellectual property, particularly since the recent announcements at Harvard University?

DNAP: Yes, the leverage at all three institutions, which includes Mass College of Pharmacy, Harvard Medical School, and Beth Israel, all three of those institutions have multiple patent application opportunities. And we believe in supporting those technologies and we will continue to do that, and we will also be looking to those patents within each of those portfolios to see what other opportunities there may be for partnering, joint venturing, licensing, or sublicensing. In addition, we made a fairly significant investment in a company called Biofrontera AG, which is moving in the direction of advancing its pharmaceutical products, and we are in continuous discussions with them about the possible licensing of products from them to the U.S. market, and then from us in the European market. So, hopefully, at some point in 2006 or 2007, Biofrontera will go public and that will help our balance sheet enormously. We own about 18% of that company.

WSR: What are the most compelling reasons that one should get involved in DNAPrint Genomics today?

DNAP: I think the most compelling reason is that we are not afraid of our science. We have been in the news quite a bit and we do some very compelling work. Our founder and visionary, Dr. Tony Frudakis, and his team of scientists, which we now have many new additions to our staff and also new partners, these are the people who have joined us, who have seen the technology and who believe in the technology as much as I do, and certainly as much as Dr. Gomez, and the rest of the team. So, I think the concept of population genetics and the concept that it can be applied across multiple fields and that we are applying it across these multiple fields is a good one, because it allows us to look at, for instance, when you go to a doctor what are the doctor’s questions? He asks you about your family. We learned a lot in genealogy because we have to study families. So, if there are hidden characteristics, i.e., the patient is in a bad way and can’t verbalize, then that’s much like a forensic detective who does not have a lot of information and has to use the genetic information to sort of unravel a puzzle. We are very good at that and we are also very good at identifying technologies. Myself and Dr. Gomez have been in the pharmaceutical industry, I hate to say how many combined years we have as we are both very “young” men. But, we like to think of ourselves as internally young, externally experienced, but I think that’s really the calling of the company. We have a well-seasoned staff; we have some very good technology; we have a vision which we are carrying forward that many people don’t understand. But it’s not always necessary for others to understand what our vision is, what is important is for our shareholders to understand our vision, and that we are applying this technology and advancing it into pharmaceuticals.

END

Back to Top
IMPORTANT NOTICE AND DISCLAIMER
Reproduction in part or in whole is strictly forbidden, except by written consent. Linking to Interviews is prohibited without express written permission of the publisher.

This is not a solicitation to buy or sell securities. Information in this Article, or Interview contains forward looking statements which involves risks and uncertainties. Actual results can differ from those discussed herein. Information contained here has not been independently verified for completeness, or accuracy and is not meant to offer a complete analysis of the companies financial condition Disclosure in compliance with the Securities and Exchange Commission\\'s 1933 Act Rule 17b: The company has purchased from Wall Street Reporter Magazine, Inc. and or its affiliates, for $6850.00 for our financial media program which usually includes the following: re-publication of this interview/article in Wall Street Reporter Magazine, hardcopy reprints of interview, server hosting of audio content, and related graphics/programming services on wallstreetreporter.com, and other media services. If payment has been issued in shares of stock of the Company so retaining the services, Wall Street Reporter Magazine will liquidate said stock when they deem it appropriate to do so. Such liquidation may have a negative impact on the securities of the Company so being sold.

TERMS OF USAGE
Use of this site is covered under the following disclaimer, terms, and conditions. Usage of this site means you, the site visitor, agreed to the following: Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. WallStreetReporter.com does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse, these views, opinions or recommendations, give investment advice, or advocate the purchase or sale of any security or investment. RealAudio Interviews are done without compensation or payment of any kind, by the interviewee / organization. However, companies do pay to have a text version of the interview published online as part of a paid media program. In Compliance with SEC Rule 17B all compensation is disclosed at the bottom of the interview page (in the case of old interviews, by clicking the Important Notice link). Quote or other Data may be delayed as specified by the Exchanges or Sources. WallStreetReporter.com furnishes this information without responsibility for accuracy and it is accepted by the site visitor on the condition that error in transmission or omissions shall not be made the basis for any claim, demand or cause for action against WallStreetReporter.com or any of its Information Providers. WallStreetReporter.com believes its content to be reliable, but accuracy is not warranted or guaranteed. The site visitor agrees not to alter the presentation, reproduce, retransmit, disseminate, sell, distribute, publish, broadcast, circulate or commercially exploit the information in any manner without the express written consent of WallStreetReporter.com; nor to use the Information for any unlawful purpose. WallStreetReporter.com may point to other sites that may of be of interest to the site visitor but for which WallStreetReporter.com has no responsibility and only provides this as a service to the site visitor.

DISCLAIMER
Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. WallStreetReporter.com does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse, these views, opinions or recommendations, give investment advice, or advocate the purchase or sale of any security or investment. RealAudio Interviews are done without compensation or payment of any kind, by the interviewee / organization. However, companies do pay to have a text version of the interview published online as part of a paid media program. In Compliance with SEC Rule 17B all compensation is disclosed at the bottom of the interview page.

IMPORTANT NOTICE
All interviews are copyright-protected intellectual property of Wall Street Reporter Magazine, Inc. Reproduction in whole or in part is strictly forbidden without written permission of the publisher. An express written license is required before linking to any interview or using any of this material in any way for reproduction in print or on another website or media without a license from the Wall Street Reporter Magazine

DNA PRINT GENOMICS INC. REGISTERED SHARES NEW DL -,01 (A0ETWM) Kurs vom 11.04. | 09:14
0,015 EUR
+0,00 | +0,00%
Xetra Berlin-Bremen Frankfurt NASDAQ OTC Bulletin Board Bid 0,015
100.000
Ask 0,025
50.000

US23324Q2021 | Aktie
n.a. | USA

Details
Eröffnung 0,015
Höchstkurs 0,015
Tiefstkurs 0,015
Vortag 0,015
Umsatz (in Stück) n.a.
Umsatz (in EUR) n.a.
Preisfeststellungen n.a.

letzte Umsätze
09:14:37 0 0,015
Handelsplätze
Name Kurs Veränderung Datum Umsatz
Xetra n.a. +0,00% 13:24 11.04. 0
Berlin-Bremen 0,017 -19,05% 09:18 11.04. 0
Frankfurt 0,015 +0,00% 09:14 11.04. 0
NASDAQ OTC Bulletin Board 0,0205 +0,00% 21:53 10.04. 0

Performance
Zeitraum Veränderung Zeitraum Datum Kurs
1 Woche +0,00% 52W Hoch 14.07.2005 0,15
1 Monat -34,78% 52W Tief 27.10.2005 0,01
1 Jahr n.a. Jahreshoch 14.02.2006 0,038
laufendes Jahr -6,25% Jahrestief 26.01.2006 0,014

Marktkapitalisierung 5,12 Mio. EUR

[Michiko]

Antwort auf Beitrag Nr.: 21.160.336 von JoJo49 am 11.04.06 15:07:25

Wo sind denn da gute Nachrichten?

Hast Du das Filing von gestern noch nicht gelesen?

[JoJo49]

Antwort auf Beitrag Nr.: 21.162.572 von Michiko am 11.04.06 17:00:29

Hast Du das Filing von gestern noch nicht gelesen?

Nein, stells bitte hier rein.
Danke und Gruß

[Michiko]

Antwort auf Beitrag Nr.: 21.173.303 von JoJo49 am 12.04.06 12:30:02

JoJo49,

einen Link zum Filing findest Du hier:

http://www.wallstreet-online.de/community/thread.html?thread…

siehe #157

Gruß

Mich

[JoJo49]

Antwort auf Beitrag Nr.: 21.176.392 von Michiko am 12.04.06 15:27:42

Danke für die Info!
Dementsprechend hat der Kurs an der NASDAQ OTC auch reagiert.
Können nur hoffen das auf Grund der positiven Nachrichten auch Umsätze folgen, ansonsten müssen wir uns in Gedult üben.
In diesem Sinn allen Anlegern weiterhin viel Erfog und gute Gedanken
DNA PRINT GENOMICS INC. REGISTERED SHARES NEW DL -,01 (A0ETWM) Kurs vom 12.04. | 16:55
0,0188 USD
-0,00 | -4,08%
NASDAQ OTC Bulletin Board Xetra Berlin-Bremen Frankfurt Bid 0,0185
5.000
Ask 0,019
10.000

US23324Q2021 | Aktie
n.a. | USA

Details
Eröffnung 0,0196
Höchstkurs 0,0198
Tiefstkurs 0,018
Vortag 0,0196
Umsatz (in Stück) 166.089
Umsatz (in USD) 3.180,29
Preisfeststellungen 15

letzte Umsätze
16:55:09 26.000 0,0188
16:54:05 5.000 0,019
16:36:18 2.947 0,018
16:29:14 19.600 0,019
16:00:28 10.000 0,019
15:59:14 5.000 0,019
15:58:05 5.000 0,019

Handelsplätze
Name Kurs Veränderung Datum Umsatz
NASDAQ OTC Bulletin Board 0,0188 -4,08% 16:55 12.04. 166.089
Xetra n.a. +0,00% 13:24 12.04. 0
Berlin-Bremen 0,016 -15,79% 09:15 12.04. 0
Frankfurt 0,016 +0,00% 09:09 12.04. 0

Performance
Zeitraum Veränderung Zeitraum Datum Kurs
1 Woche -6,82% 52W Hoch 12.07.2005 0,179
1 Monat -16,33% 52W Tief 07.11.2005 0,0019
1 Jahr n.a. Jahreshoch 17.03.2006 0,034
laufendes Jahr -2,84% Jahrestief 19.01.2006 0,0165

Fundamentaldaten
2005 2006e 2007e
Gewinn pro Aktie n.a. n.a. n.a.
KGV n.a. n.a. n.a.
Dividendenrendite 0,0% 0,0% 0,0%
Marktkapitalisierung 5,12 Mio. EUR

[brokersvenja007]

Detailed Quote Snapshot 04/13/2006 09:45 AM
Last:

0.022 dnag - DNAPRINT GENOMICS INC
Change:

% Change:

% High:

0.022 Low:

0.02 Volume:

3,816,434


sieht doch super aus heute...grüße
svenja

[Trooper2]

Market Pulse Breaking News Alert for Thursday, April 13, 2006: DNAG -- DNAPrint Genomics Ancestry Technology Highlighted in Article in the New York Times!
Market Pulse News Alert for this AM, Stocks to Watch are: DNAPrint Genomics, Inc. (OTC BB: DNAG), SanDisk Corp. (NASDAQ: SNDK), Novavax Inc. (NASDAQ: NVAX) and Veridium Corp.(OTC BB: VRDM).

Investors need to be watching DNAPrint Genomics, Inc. (OTC BB: DNAG) this AM! DNAPrint is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology, and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness(TM), RETINOME(TM) (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA(TM), and EURO-DNA(TM). DNAPrint's management sees exciting growth opportunity in these markets to introduce and sell their novel products and services. DNAG has had several excellent news announcements out lately and one again before today's opening bell announcing their Ancestry technology was highlighted in an article in The New York Times! Investors should be watching this one closely!

DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that the Company's technology was highlighted in an article entitled "Seeking Ancestry in DNA Ties Uncovered by Tests" in the April 12, 2006 edition of The New York Times.

The article reported that genetic tests, once obscure tools for scientists, have begun to influence everyday lives in many ways and that people are utilizing them when applying for jobs and college scholarships. "The tests are reshaping people's sense of themselves -- where they come from, why they behave as they do, what disease might be coming their way," The Times reported.

Commenting on the article following its publication, DNAPrint President and Chief Executive Officer Richard Gabriel said that there is a growing interest and demand for the Company's ANCESTRYbyDNA(TM) technology for determining family heritage. "In many instances, people who take the test want to determine whether they have American Indian or other ancestry to validate eligibility for college admission or scholarship programs. DNAPrint Genomics maintains the largest Native American DNA Database in North America."

In addition to its ANCESTRYbyDNA(TM) test for determining family heritage, DNAPrint Genomics' technology has forensic applications. The Company's DNAWITNESS(TM) product analyzes DNA taken from crime scenes, and has been utilized in more than 100 criminal investigations worldwide. DNAWITNESS(TM) test results have assisted investigators in many high profile criminal cases, including the apprehension and conviction of a serial killer in Louisiana. The article can be accessed on the newspaper's web site at http://www.nytimes.com/2006/04/12/us/12genes.html?ei=5094&en…

[Lostocos]

NEWS: DER BERICHT IST DA!!!

http://www.pinksheets.com/quote/print_filings.jsp?url=%2Fred…

[Lostocos]

Dnag hat nun einen 3. Boden ausgebildet (weiße Punkte) mit einer neuen Trendlinie (gelb).

DNAG sollte jetzt wieder von Neuem starten, nur dann hoffe ich, daß sie für immer die Marke von 0,02 USD hinter sich lässt. Wir werden sehen...

[Michiko]

Antwort auf Beitrag Nr.: 21.244.204 von Lostocos am 19.04.06 19:33:51

Lostocos,

ich habe den Chart mitsamt Deinem Kommentar in ein US-Board gestellt.
Hoffe, Du hast nichts dagegen.

Michi

[Quipu]

DNAPrint Genomics President Richard Gabriel Discusses Genomics Technology During Interview on National Public Radio
Tuesday April 18, 10:46 am ET


SARASOTA, Fla., April 18, 2006 (PRIMEZONE) -- DNAPrint Genomics, Inc. (OTC BBNAG.OB - News) today announced that President and Chief Executive Officer Richard Gabriel discussed a broad range of issues relating to the Company's complex genomics classification technology in an interview with National Public Radio on Monday, April 17th.
ADVERTISEMENT


In an interview with Robin Young on the ``Here & Now'' program facilitated by Boston radio station WBUR, Mr. Gabriel discussed the Company's applications for DNA testing to determine family heritage, law enforcement forensics and new drug development.

``We're able to give people an understanding of what regions of the world their genetic ancestors came from,'' said Mr. Gabriel. ``We're working with the FBI to help identify serial killers and with Scotland Yard (where) there's a rapist in London who has been operating over 13 years. We also work in the area of pharmacogenomics, where understanding human genetic populations is important to understanding drug metabolism and also understanding disease.''

When asked about criticism of the technology, including claims that DNA tests are too diluted to give an accurate ancestry picture, Mr. Gabriel responded: ``It's such a new field. I liken it to discovering a continent. We don't know yet what the paths are. We don't know yet all of the secrets that are contained in the DNA. And I think it would be a mistake to restrict the exploration of this new continent by condemning or barring the use of this technology by anyone.''

Mr. Gabriel's interview can be heard via webcast by accessing http://www.here-now.org/shows/2006/04/20060417.asp .

[Quipu]

http://www.here-now.org/shows/2006/04/20060417.asp

[Quipu]

Jaaaaaaaaaaa!! Weiter gehts!!


DNAPrint Genomics Receives Notice of Allowance for Patent for Identifying Links Between Gene Sequences and Medical Traits
Thursday April 20, 7:00 am ET


Sophisticated Technology Utilized by Company's DNAPrint Pharmaceuticals Subsidiary


SARASOTA, FL--(MARKET WIRE)--Apr 20, 2006 -- DNAPrint Genomics, Inc. (OTC BBNAG.OB - News) today announced that the Company has received a Notice of Allowance from the U.S. Patent and Tradmark Office for a patent application, Methods for the Identification of Genetic Features for Complex Genetics Classifiers. The patent protects the Company's methods for identifying links between gene sequences and phenotypes (physical or medical traits).
ADVERTISEMENT


"Gene sequences are highly polymorphic in the population, which means that they come in various forms or 'flavors,'" stated DNAPrint Genomics Founder and Chief Scientific Officer Tony N. Frudakis. "Polymorphism is usually measured at the level of the single nucleotide polymorphism (SNP) but our technology measures at the level of the haplotype (strings of SNPs), which provides researchers considerably more information. The methods covered in the patent allow for an efficient and powerful means for identifying haplotype."

The recent patent provides legal protection for DNAPrint's status as one of a very few companies currently capable of performing objective, assumption-free haplotype analyses. DNAPrint is also the only company currently using Ancestry Informative Markers (AIMs) and has patents pending in this area as well. Because of limitations with traditional genome screening methods and the complex genetic characteristics of modern populations, AIMS are integral to the development of DNA tests for the inference of genetic ancestry based on phenotypes, including identifying certain physical characteristics, or an individual's predisposition to respond to certain drugs.

"The Company is committed to developing a new class of drugs, called 'theranostics,' which are test+drug combinations designed to help ensure that patients receive the appropriate medicine and proper dosage based on their genetic constitution. The application of theranostics is also designed to increase efficacy and reduce side-effects," said DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D. "Our sophisticated genetics technology is playing a key role in the research and development of potential new drugs."

"This patent cuts across a wide audience of developers from drug companies to people working on technology in the forensics and consumer areas," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We plan to vigorously utilize and practice our patents and we will be reviewing the fields of genetic testing, drug development, forensic sciences and consumer products with our patent counsel to determine potential areas of development. We want to ensure that we extract the greatest economic value out of this patent for our shareholders and investors."

DNAPrint Genomics currently holds two patents and has several others pending or in the hands of patent counsel.

[Quipu]

DNAPrint Genomics Erhält Benachrichtigung der Erlaubnis für das Patent, um Verbindungen Zwischen Genfolgen und Medizinischen Charakterzügen Donnerstag, der 20. April, 7 Uhr 00 UND Hoch entwickelter Technologie Verwertet durch die DNAPrint Arzneimittel-Tochtergesellschaft der Gesellschaft SARASOTA, FL - (MARKTLEITUNG) - am 20. Apr 2006 Zu identifizieren - DNAPrint Genomics, Inc (OTC BBNAG.OB - Nachrichten) gab heute bekannt, dass die Gesellschaft eine Benachrichtigung der Erlaubnis vom US-amerikanischen Patent und Tradmark Büro für eine offene Anwendung, Methoden für die Identifizierung von Genetischen Eigenschaften für die Komplizierte Genetik Classifiers erhalten hat. Das Patent schützt die Methoden der Gesellschaft, um Verbindungen zwischen Genfolgen und Phänotypen (physische oder medizinische Charakterzüge) zu identifizieren. ANZEIGE "Genfolgen ist in der Bevölkerung hoch polymorph, was bedeutet, dass sie in verschiedenen Formen oder 'Geschmäcke kommen,'" setzte DNAPrint Genomics Gründer und Wissenschaftlicher Hauptoffizier Toni N. Frudakis fest. " Polymorphism wird gewöhnlich am Niveau des einzelnen nucleotide polymorphism (SNP) aber unserer Technologiemaßnahmen am Niveau des haplotype gemessen (Schnuren von SNPs), der Forschern beträchtlich mehr Auskunft gibt. Die im Patent bedeckten Methoden berücksichtigen ein effizientes und starkes Mittel, haplotype zu identifizieren. " Das neue Patent stellt gesetzlichen Schutz für den Status von DNAPRINT als eine von ganz wenigen Gesellschaften zurzeit fähig dazu zur Verfügung, objektive, Haplotype-Analysen ohne Annahme durchzuführen. DNAPrint ist auch die einzige Gesellschaft, die zurzeit Herkunft Informative Anschreiber (ZIELE) verwendet, und hat Patente während in diesem Gebiet ebenso. Wegen Beschränkungen mit dem traditionellen Genom, das Methoden und die komplizierten genetischen Eigenschaften von modernen Bevölkerungen schirmt, sind ZIELE zur Entwicklung von DNA-Tests für die Schlussfolgerung der genetischen Herkunft beruhend auf Phänotypen, einschließlich des Identifizierens bestimmter physischer Eigenschaften, oder einer Geneigtheit einer Person integriert, um auf bestimmte Rauschgifte zu antworten. " Die Gesellschaft wird das Entwickeln einer neuen Klasse von Rauschgiften, genannt 'theranostics' verpflichtet, die test+drug Kombinationen dafür entworfen sind zu helfen sicherzustellen, dass Patienten die passende Medizin und richtige auf ihre genetische Zusammensetzung beruhende Dosierung erhalten. Die Anwendung von theranostics wird auch dafür entworfen, Wirkung zu vergrößern und Nebenwirkungen zu reduzieren," sagte der DNAPrint Vorsitzende und Hauptamtsarzt Hector J. Gomez, M.D., Dr. "Unsere hoch entwickelte Genetik-Technologie spielt eine Schlüsselrolle in der Forschung und Entwicklung von potenziellen neuen Rauschgiften." "Dieses Patent schneidet über ein breites Publikum von Entwicklern von Drogenfirmen bis Leute, die an der Technologie im forensics und Verbrauchergebieten arbeiten," setzte der DNAPrint Präsident und Geschaftsführer Richard Gabriel fest. " Wir planen, kräftig zu verwerten und unsere Patente zu üben, und wir werden die Felder der genetischen Prüfung, Rauschgift-Entwicklung, forensischen Wissenschaften und Verbrauchsgüter mit unserem offenen Anwalt nachprüfen, um potenzielle Gebiete der Entwicklung zu bestimmen. Wir wollen sicherstellen, dass wir den größten Wirtschaftswert aus diesem Patent für unsere Aktionäre und Kapitalanleger herausziehen. "DNAPrint Genomics hält zurzeit zwei Patente und hat mehrere andere während oder in den Händen des offenen Anwalts.

[Quipu]

...um potenzielle Gebiete der Entwicklung zu bestimmen. Wir wollen sicherstellen, dass wir den größten Wirtschaftswert aus diesem Patent für unsere Aktionäre und Kapitalanleger herausziehen.

[JoJo49]

Antwort auf Beitrag Nr.: 21.254.949 von Quipu am 20.04.06 14:43:57

Na ja, haben schon viel erzählt bzw. veröffentlicht.
Können als Anleger nur hoffen, das sie mal in die Spur kommen, denn m.M. nach wir d hier zu sehr gezockt.
Man muß sich hie nur die Umsätze anschauen - sind gigantisch nur es kommt nichts bei rüber und keiner wird schlau daraus.
Hier ist Geduld und Spucke angesagt!
DNA PRINT GENOMICS INC. REGISTERED SHARES NEW DL -,01 (A0ETWM) Kurs vom 24.04. | 10:50
0,015 EUR
+0,00 | +0,00% NASDAQ OTC Bulletin Board Xetra Frankfurt Berlin-Bremen Bid 0,011
100.000
Ask 0,019
100.000

US23324Q2021 | Aktie
n.a. | USA

Details
Eröffnung 0,015
Höchstkurs 0,015
Tiefstkurs 0,015
Vortag 0,015
Umsatz (in Stück) 50.000
Umsatz (in EUR) 750,00
Preisfeststellungen 2

letzte Umsätze
10:50:48 50.000 0,015
09:08:41 0 0,015
Handelsplätze
Name Kurs Veränderung Datum Umsatz
NASDAQ OTC Bulletin Board 0,0195 -3,94% 18:25 24.04. 677.300
Xetra n.a. +0,00% 13:24 24.04. 0
Frankfurt 0,015 +0,00% 10:50 24.04. 50.000
Berlin-Bremen 0,016 -5,88% 09:33 24.04. 0

Performance
Zeitraum Veränderung Zeitraum Datum Kurs
1 Woche +6,67% 52W Hoch 14.07.2005 0,15
1 Monat -27,27% 52W Tief 27.10.2005 0,01
1 Jahr n.a. Jahreshoch 14.02.2006 0,038
laufendes Jahr +0,00% Jahrestief 26.01.2006 0,014

[JoJo49]

Antwort auf Beitrag Nr.: 21.254.949 von Quipu am 20.04.06 14:43:57

In den USA tut sich was, weiß jemand warum - ansonsten ist wohl der Boden entgülitig erreicht und es kann nur noch steil bergauf gehen.
In diesem Sinn allen Anlegern weiterhin viel Erfolg und gute Gedanken

USA
Handelsplätze
Name Kurs Veränderung Datum Umsatz
NASDAQ OTC Bulletin Board 0,0195 +5,41% 21:22 09.05. 1.951.367

[Onkelbaer]

Antwort auf Beitrag Nr.: 21.504.437 von JoJo49 am 10.05.06 13:35:40

Was genau meinst Du! Was soll sich tun?

Erleuchte uns!

Greets Onkelbaer